Page last updated: 2024-12-04

alpha-hydroxymyristic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-hydroxymyristic acid : A long-chain fatty acid that is a derivative of myristic acid having a hydroxy substituent at C-2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1563
CHEMBL ID2004471
CHEBI ID59270
SCHEMBL ID123324
MeSH IDM0068138

Synonyms (75)

Synonym
CHEBI:59270 ,
alpha-hydroxymyristic acid
CBIOL_001998
1-(2,4,6-trichlorophenyl)-3-(3-nitrobenzamido)-5-pyrazolone
NCI60_001578
NCIMECH_000236
BSPBIO_001417
nsc-18938
2507-55-3
2-hydroxymyristic acid
nsc18938 ,
tetradecanoic acid, 2-hydroxy
2-hydroxytetradecanoic acid
.alpha.-hydroxymyristic acid
tetradecanoic acid, 2-hydroxy-
BIO2_000617
BIO1_000284
BIO1_000773
BIO1_001262
BIO2_000137
IDI1_033887
NCGC00179204-01
alpha-hydroxy-n-tetradecylic acid
2-hydroxytetradecanoic acid, >=98% (capillary gc)
NCGC00161354-01
NCGC00161354-02
KBIOSS_000137
KBIO3_000274
KBIO2_002705
KBIOGR_000137
KBIO2_000137
KBIO2_005273
KBIO3_000273
alpha-hydroxymyristate
HMS1989G19
BML3-C05
HMS1791G19
HMS1361G19
AKOS003238538
NCGC00161354-03
nsc 18938
einecs 219-714-0
tetradecanoic acid, hydroxy-
FT-0612626
dl-alpha-hydroxymyristic acid
SCHEMBL123324
CHEMBL2004471 ,
JYZJYKOZGGEXSX-UHFFFAOYSA-N
.alpha.-hydroxy-n-tetradecylic acid
HMS3402G19
HMS3649L19
tetradecanoic acid,2-hydroxy-
LMFA01050484
alpha-hydroxy-n-tetradecylate
2-hydroxy-myristic-acid
a-hydroxymyristic acid
dl-a-hydroxymyristic acid
a-hydroxymyristate
dl-alpha-hydroxymyristate
a-hydroxy-n-tetradecylate
dl-a-hydroxymyristate
hydroxytetradecanoic acid
J-015803
d,l-|a-hydroxy myristic acid
BCP25476
DTXSID10862974
Q27126580
a-hydroxy-n-tetradecylic acid
sr-01000946676
SR-01000946676-1
A902159
bdbm50511008
d,l-?-hydroxy myristic acid
PD011763
BP-29864
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
2-hydroxy fatty acidAny fatty acid with a hydroxy functional group in the alpha- or 2-position.
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)Ki0.31800.02361.29013.3100AID1546369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)EC50 (µMol)4.11000.08903.868710.0000AID1546364; AID1546366
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
biological_processG-protein coupled receptor 84Homo sapiens (human)
neuropeptide signaling pathwayG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
urotensin II receptor activityG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
specific granule membraneG-protein coupled receptor 84Homo sapiens (human)
tertiary granule membraneG-protein coupled receptor 84Homo sapiens (human)
receptor complexG-protein coupled receptor 84Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1546366Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546369Displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546370Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay relative to embelin2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546364Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546365Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 m2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (25.93)18.2507
2000's11 (40.74)29.6817
2010's6 (22.22)24.3611
2020's3 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.15 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]